ADGRL2 and prostate cancer: ChIP assay in prostate cancer cells further revealed interactions of full-length ARs, as well as AR-V7 implicated in developing castration-resistant disease, with LPHN1, LPHN2, or LPHN3 at its promoter region, indicating the direct regulation of the expression of each LPHN by ARs.